🔎 Trials Near Me

Home › Malattia di Crohn › Ohio

Studi clinici su Malattia di Crohn nello stato di Ohio

30 studi su Malattia di Crohn cercano partecipanti presso sedi nello stato di Ohio.

Città nello stato di Ohio

Testo ufficiale dello studio (inglese)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07697456

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
In reclutamentoVolontari sani benvenuti
Età da 18 a 75 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07852273

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health Research - Cincinnati, Cincinnati
  • DSI Research Northridge LLC, Dayton
  • Gastro Health Research - Liberty Township, Liberty Township
  • e altri 3
In reclutamentoFase 4
Età da 18 a 80 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06581328

Non-nutritive Sweeteners in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
In reclutamentoVolontari sani benvenuti
Età da 18 a 70 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07769437

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • University of Cincinnati /ID# 265589, Cincinnati
  • The Ohio State University /ID# 265577, Columbus
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07499232

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 3
Età 3 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06663332

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
  • University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
  • Ohio Gastroenterology Group Inc.-8400006, Columbus
  • e altri 5
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
  • Medical Associates Research Group-Site Number: 8400063, Columbus
  • OSU Wexner Medical Center-Site Number: 8400077, Columbus
  • e altri 1
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Cleveland Clinic - Cleveland /ID# 256453, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05995353

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Cincinnati, Cincinnati
  • Ohio Gastroenterology group, Inc., Columbus
  • Great Lakes Gastroenterology Research, LLC, Mentor
  • e altri 1
In reclutamentoFase 4
Età da 18 a 70 · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06045754

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07577843

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

  • Cleveland Clinic, Cleveland
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07680283

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Childrens Medical Center, Dayton
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05509777

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of Cincinnati, Cincinnati
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07237516

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • UH Cleveland Medical Center /ID# 262188, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Children's Clinic, Cleveland
  • Cleveland Clinic, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • UH/Rainbow Babies and Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
In reclutamentoFase 4
Età da 6 a 17 · Tutti i sessi · Aggiornato il 27 mag 2026 · NCT05781152

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
In reclutamentoFase 3
Età 2 e oltre · Tutti i sessi · Aggiornato il 7 mag 2026 · NCT05442567

Precise Infliximab Exposure and Pharmacodynamic Control

  • Cincinnati Children's Hospital, Cincinnati
  • Cleveland Clinic Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
In reclutamentoFase 2/3
Età da 6 a 22 · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT05660746

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04779320

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • OSU Inflammatory Bowel Disease Center, Hilliard
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 27 apr 2026 · NCT06456593

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Cincinnati
  • Mirador Therapeutics Selected Site, Liberty Township
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 12 mar 2026 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Cleveland Clinic, Cleveland
In reclutamentoFase 1/2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT06721962

Evaluation of the SMART IBD App in Pediatric IBD

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamento
Età da 13 a 17 · Tutti i sessi · Aggiornato il 21 nov 2025 · NCT07195123

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

  • Cleveland Clinic Foundation, Cleveland
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 nov 2025 · NCT06670638

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.